Trial reportBMJ open2014
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
Trial report in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01692301 (A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide.Journal of hypertension · 2019Trial
- Age- and sex-related reference values for central blood pressure parameters in middle-aged and older Japanese adults: the Wakayama study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Measures of wave intensity as a non-invasive surrogate for cardiac function predicts mortality in haemodialysis patients.Clinical kidney journal · 2024Article
- Arterial stiffness as a risk factor for clinical hypertension.Nature reviews. Cardiology · 2018Review
- The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.Current cardiology reports · 2018Review
- Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Journal of biological engineering · 2018Review
- The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Archives of medical science : AMS · 2017Article
- Hypertension up to date: SPRINT to SPYRAL.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Review
- Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.Current cardiology reports · 2016Review
- Vascular ageing and interventions: lessons and learnings.Therapeutic advances in cardiovascular disease · 2016Review
- Drug discovery in renin-angiotensin system intervention: past and future.Therapeutic advances in cardiovascular disease · 2016Review
- Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.Drug design, development and therapy · 2016Review
- The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Clinical science (London, England : 1979) · 2016Review
- Sacubitril/Valsartan.Hospital pharmacy · 2015Article
- Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2015Review
- New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Current hypertension reports · 2015Review
- Neprilysin inhibition in chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Review
- Novel RAAS agonists and antagonists: clinical applications and controversies.Nature reviews. Endocrinology · 2015Review
- Natriuretic Peptides as a Novel Target in Resistant Hypertension.Current hypertension reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
introductionHypertension in elderly people is characterised by elevated systolic blood pressure (SBP) and increased pulse pressure (PP), which indicate large artery ageing and stiffness. LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is being developed to treat hypertension and heart failure. The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study will assess the efficacy of LCZ696 versus olmesartan on aortic stiffness and central aortic haemodynamics. METHODS AND ANALYSIS: In this 52-week multicentre study, patients with hypertension aged ≥60 years with a mean sitting (ms) SBP ≥150 to <180 and a PP>60 mm Hg will be randomised to once daily LCZ696 200 mg or olmesartan 20 mg for 4 weeks, followed by a forced-titration to double the initial doses for the next 8 weeks. At 12-24 weeks, if the BP target has not been attained (msSBP <140 and ms diastolic BP <90 mm Hg), amlodipine (2.5-5 mg) and subsequently hydrochlorothiazide (6.25-25 mg) can be added. The primary and secondary endpoints are changes from baseline in central aortic systolic pressure (CASP) and central aortic PP (CAPP) at week 12, respectively. Other secondary endpoints are the changes in CASP and CAPP at week 52. A sample size of 432 randomised patients is estimated to ensure a power of 90% to assess the superiority of LCZ696 over olmesartan at week 12 in the change from baseline of mean CASP, assuming an SD of 19 mm Hg, the difference of 6.5 mm Hg and a 15% dropout rate. The primary variable will be analysed using a two-way analysis of covariance. ETHICS AND DISSEMINATION: The study was initiated in December 2012 and final results are expected in 2015. The results of this study will impact the design of future phase III studies assessing cardiovascular protection. CLINICAL TRIALS IDENTIFIER: EUDract number 2012-002899-14 and ClinicalTrials.gov NCT01692301.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.